We’re excited to share that the FDA has accepted our NDA for bezuclastinib in patients with AdvSM. It's our third NDA acceptance this year! We’re deeply grateful to the patients, families, & investigators and the entire Cogent team. bit.ly/4ipkjpv

Today we reported our second quarter 2026 financial results and recent business highlights. Read the full press release here: bit.ly/4cvhT4G

The #GISTCommunity has always had a powerful voice. At #LifeFest2026 in Nashville those voices were captured on the GIST community guitar thru messages of strength, hope, & encouragement. TY to everyone who shared a message & to @liferaftgroup for bringing the community together.

We’re thrilled to announce that we've submitted our third New Drug Application (NDA) to the U.S. FDA with bezuclastinib; this one for #AdvSM! This submission is a testament to the tireless work of our team and our dedication to patients. Read our PR here: bit.ly/4bgnqeQ

Last week we welcomed Patient Advocacy Leaders from the rare disease & cancer communities to our first Elevation Summit in Boulder. Participants shared valuable expertise & perspectives that will help inform future action & deepen our collective impact. TY to all who contributed!

We’re in Stockholm for #EHA2026 presenting updated data from our APEX trial in AdvSM as well as pathobiology data in AdvSM & preclinical data from our JAK2 V617F program. Read more here: bit.ly/43x57xT and find our posters & presentations here: bit.ly/4dGfBkx

Today we shared detailed clinical data and updates from our #GIST program being presented at #ASCO26. Read the release: bit.ly/4uES49o and find the presentation here: bit.ly/4dGfBkx

Our team is heading to the #ASCO26 where we’re presenting detailed clinical data in Gastrointestinal Stromal Tumors #GIST. We hope to see you there!

We’re thrilled to share that the FDA has accepted our 2nd NDA this year! Our combo of bezuclastinib + sunitinib for patients w/#GIST received Priority Review! We're deeply grateful to the patients, families, investigators & entire Cogent team. Read more: bit.ly/4va65vK

Join us for a fireside chat at the @Jefferies Global Healthcare conference in New York on June 3 at 11:05am ET. Register and listen to the webcast here. bit.ly/4wSfRnN #JefferiesHealthcare

We’re excited to present pivotal data from our APEX trial in #AdvSM & preclinical data from our emerging JAK2 V617F program at #EHA2026. We look forward to seeing you in Stockholm & connecting w/the hematology community! Find presentation details here bit.ly/4wqTG83.

Today we reported our first quarter 2026 financial results, highlighting continued momentum with bezuclastinib and our pipeline. Read more here: bit.ly/49c71am

We’re pleased to share that the Phase 3 PEAK trial has been selected for an oral presentation at #ASCO26. We’ll present data from our trial of bezuclastinib in combo w/sunitinib in patients w/GIST who have received prior treatment w/imatinib. Read more: bit.ly/3QzSaA4

At #AACR26 we’re presenting new preclinical data on our pan-KRAS inhibitor showcasing its selectivity profile which could lead to reduction in skin tox & from our brain penetrant ErbB2 inhibitor w/evidence of synergistic activity in combo w/HER2 ADCs. PR: bit.ly/4enZFnC

Today we announced we've submitted our second New Drug Application to the U.S. FDA with bezuclastinib; this one for #GIST! The NDA was submitted under the FDA’s RTOR program. It’s another important milestone for patients & for Cogent! Read our PR: bit.ly/48nRd3R

We're excited to share that the FDA has accepted our NDA for bezuclastinib in patients with NonAdvanced SM. We’re thankful to the patients, families, investigators & the entire Cogent team who made this significant achievement possible. Read more: bit.ly/4cLC2Vi

Cogent is driven by our commitment 2 advancing therapies 4 those living w/#SystemicMastocytosis & #GIST. On #RareDiseaseDay , we wore stripes 2 raise awareness, show our support 4 the #SM & #GIST communities, & reflect on the people who inspire our work each day. #ShowYourStripes

We’re excited to be at the #AAAAI26 ! Today we’re presenting data from 6 bezuclastinib posters. Read the release bit.ly/4u27RiQ and find the posters here bit.ly/40x1vue. If you missed us at the poster sessions come see us in booth 917 in the Exhibit Hall!

Our team is heading to the American Academy of Allergy, Asthma & Immunology Annual Meeting where we’re presenting six SUMMIT posters in NonAdvanced SM. The Exhibit Hall opens Feb 27 and our posters are Feb 28 at 9:45am ET. We hope to see you there! #NonAdvSM #AAAAI26

Today we shared our 4QFY 2025 financial results and recent business highlights. We’re proud of our progress and look forward to what’s ahead. Read the full press release here: bit.ly/4kIQvDm